• 1. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 4. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Professional Introduction to 3,6-Dimethylpiperazine-2,5-dione (CAS No. 5625-46-7)

3,6-Dimethylpiperazine-2,5-dione, identified by the Chemical Abstracts Service Number (CAS No.) 5625-46-7, is a significant heterocyclic compound that has garnered considerable attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the piperazine derivatives family, which is well-known for its diverse pharmacological properties and applications in drug development. The unique structural framework of 3,6-Dimethylpiperazine-2,5-dione, featuring two methyl groups at the 3 and 6 positions and a diketone moiety at the 2 and 5 positions, contributes to its distinctive chemical behavior and biological activity.

The compound’s molecular structure imparts a high degree of reactivity, making it a valuable intermediate in synthetic organic chemistry. Its diketone functional groups facilitate various chemical transformations, including condensation reactions, Michael additions, and cycloadditions, which are pivotal in constructing more complex molecular architectures. These synthetic capabilities have positioned 3,6-Dimethylpiperazine-2,5-dione as a versatile building block for the synthesis of pharmacologically active agents.

In recent years, 3,6-Dimethylpiperazine-2,5-dione has been extensively studied for its potential applications in medicinal chemistry. The piperazine core is a common scaffold in many drugs due to its ability to interact with biological targets such as enzymes and receptors. Researchers have explored its derivatives as candidates for treating neurological disorders, infectious diseases, and inflammatory conditions. The presence of methyl groups at the 3 and 6 positions enhances lipophilicity, which can improve membrane permeability and bioavailability of drug molecules.

One of the most promising areas of research involving 3,6-Dimethylpiperazine-2,5-dione is its role in developing novel antimicrobial agents. The increasing prevalence of antibiotic-resistant pathogens has underscored the need for innovative therapeutic strategies. Studies have demonstrated that certain derivatives of this compound exhibit potent activity against Gram-positive and Gram-negative bacteria. The diketone moiety plays a crucial role in disrupting bacterial cell wall synthesis and inhibiting key metabolic pathways. This has opened up new avenues for combating multidrug-resistant infections.

Furthermore, 3,6-Dimethylpiperazine-2,5-dione has been investigated for its potential in treating neurological disorders such as epilepsy and Parkinson’s disease. Piperazine derivatives are known to modulate neurotransmitter systems by acting on receptors such as dopamine receptors and serotonin receptors. Preclinical studies have shown that certain analogs of 3,6-Dimethylpiperazine-2,5-dione can attenuate seizure activity and improve motor function in animal models. These findings suggest that this compound may serve as a lead compound for developing new anticonvulsant and neuroprotective agents.

The synthesis of 3,6-Dimethylpiperazine-2,5-dione involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Common synthetic routes include condensation reactions between appropriate precursors followed by cyclization steps. Advances in catalytic methods have enabled more efficient and sustainable synthesis of this compound. For instance, transition metal-catalyzed reactions have been employed to streamline the formation of the piperazine ring and the diketone functional groups.

The pharmacokinetic properties of 3,6-Dimethylpiperazine-2,5-dione derivatives are also subjects of intense research. Factors such as solubility, stability, absorption rate, distribution volume, metabolism rate (via Phase I and Phase II pathways), and excretion rate are critical determinants of drug efficacy and safety. Computational modeling techniques have been increasingly utilized to predict these properties before experimental validation. This approach accelerates the drug discovery process by allowing researchers to optimize molecular structures for improved pharmacokinetic profiles.

In conclusion,3 ,6-Dimethyl piperazine - 2 ,5 - dione ( CAS No . 5625 -46 -7 ) represents a structurally intriguing compound with broad applications in pharmaceutical research . Its unique chemical properties make it an invaluable intermediate for synthesizing biologically active molecules . Ongoing studies continue to uncover new therapeutic potentials , particularly in antimicrobial therapy , neurology ,and other areas where novel drug candidates are urgently needed . As research progresses , further refinements in synthetic methodologies will likely enhance accessibility , paving the way for more comprehensive exploration of its pharmacological significance . p>

• 4526-77-6(Cyclo(L-Ala-L-Gly))
• 434314-23-5(2,6-Piperazinedione,3-methyl-, (3R)-)
• 88547-15-3(2,5-Piperazinedione,3-methyl-, (3R)-)
• 78551-38-9((3S)-3-methylpiperazin-2-one)
• 72904-45-1(2,5-Piperazinedione, 3,6-dimethyl-, (3R,6R)-rel-)
• 5845-61-4((3S,6S)-3,6-dimethylpiperazine-2,5-dione)
• 434314-22-4(2,6-Piperazinedione,3-methyl-,(3S)-(9CI))
• 234108-28-2(2-Piperazinone,3,5-dimethyl-, (3S)-)
• 647854-51-1(Methyl, [(2R,5R)-5-methyl-3,6-dioxo-2-piperazinyl]-, rel-)
• 922178-61-8((3R)-3-methylpiperazin-2-one)